Inify Laboratories

Interim report for the second quarter 2026

This is Inify Laboratories

Who we are
Inify Laboratories is based in Sweden and its shares are listed on Euronext Growth Oslo. The company has two subsidiaries; Inify Laboratories Nordics AB and Inify Laboratories Ltd.

How we do it
Inify has built a unique and ultramodern laboratory and developed a fully digital, standardized and AI-assisted workflow in order to optimize quality and shorten response times. The diagnostic services is offered for selected cancer types, where specialization contributes to high and reliable quality.

What we do
Inify Laboratories provides cancer diagnostics in histopathology. Our laboratory offers diagnostic services to both public and private healthcare providers. The business model and technical structure allow for scalability in volume, diagnosis and geographical expansion.

Why we do it
Clinical pathology is currently under great pressure, with high workloads and limited – even declining – resources. An aging population, increasing cancer incidence, and more frequent examinations and screening programmes further increase the workload. Solving the problem through labor alone is not an option, it is necessary to work in new ways.

Our vision:
World leading diagnostics for everyone!

Second quarter highlights

- Net sales 6.3 MSEK (5.6)
- Approval from Care Quality Commission (CQC) in the UK
- Signed customer agreement and launch of services in the UK
- Signed customer agreement in Sweden

Key figures	Q2 2026	Q2 2025	6 months 2026	6 months 2025	Full year 2025
Average number of shares	93 189 130	62 070 083	93 189 130	62 070 083	62 070 083
Earnings per share (SEK)	-0.20	-0.22	-0.40	-0.41	-0.86
Solidity	90.0%	92.1%	90.0%	92.1%	75.8%
Sales (TSEK)	7 631	5 603	13 930	10 782	22 228
EBITDA (TSEK)	-18 147	-16 634	-36 237	-31 129	-64 797
Cash at period end	90 658	129 740	90 658	129 740	57 532

The company use some figures that are considered as Alternative Performance Measures.
Please see description under section Alternative Performance Measures and Definitions.

Letter from the CEO

Successful launch of our laboratory and services in the UK

The second quarter has been characterised by multiple milestones. The signing of our first contract and the commencement of delivery of our services in the UK represents a significant breakthrough. This, together with new agreements in Sweden and important regulatory approvals in both countries, provides good conditions for the next phase of growth.

> “An evaluation agreement with University Hospital Plymouth NHS Trust (UHP) was signed in June.”

Progress in the UK

Several important milestones fell into place, bringing us ever closer to establishing ourselves in the market. The UK laboratory is now completed and, following an extensive review, the laboratory operations received regulatory approval from the Care Quality Commission (CQC). This is clear proof of quality and a requirement for conducting routine clinical diagnostics for the country’s healthcare system.

An evaluation agreement with University Hospital Plymouth NHS Trust (UHP) was signed in June – a very important step forward and a significant entry as a diagnostics provider to the public healthcare system in the UK. The agreement includes continuous delivery of our services with a focus on jointly streamlining diagnostics, shortening lead times and thereby improving patient pathways. Initially, patient sample volumes will be limited but are expected to gradually increase. Inify is responsible for the entire chain of logistics, sample preparation, and digitisation of the patient samples, giving the hospital’s pathologists the opportunity to perform diagnostics remotely in Inify’s system. The first samples were received at the end of June. The agreement and our deliveries are of great importance, as they also strengthen our position in ongoing dialogues with additional regions and hospitals across the country. We are optimistic about being able to sign additional agreements during the year.

> "An important milestone during the quarter was the award of a tender with Region Jämtland Härjedalen."

Study visits to our laboratory are an important part of the dialogue with potential customers. During the period, we have had several visits and the response has been consistently positive. Visitors gain a clear sense that we have designed our laboratory operations with a unique holistic perspective. This is key to delivering diagnostics that drive significant improvements for referring physicians and diagnosticians, ultimately resulting in an efficient care pathway for the patient.

In June, we participated in BAUS, the national British urology congress in London, where leading urologists from across the country gather. The congress provided good opportunities to expand and build on our network of key contacts in the field of prostate cancer.

We continue to maintain a clear focus on the public health service (NHS) in the UK, as they handle the vast majority of patients undergoing prostate cancer investigations.

Operations in Sweden

Sales continue to grow, and an important milestone during the quarter was the award of a tender with Region Jämtland Härjedalen. The agreement included the delivery of complete prostate cancer diagnostics for all patients in the region, beginning mid-quarter. This is another important step forward and a reference for other regional customers in Sweden, where we have several ongoing dialogues.

The laboratory in Sweden received accreditation to ISO 15189 for gastrointestinal diagnostics (GI), where we have delivered our services to a small number of customers so far. In June, an evaluation agreement for GI samples was signed with Region Västmanland, with service delivery expected to begin after the summer. The agreement involves a collaboration in which we deliver logistics, sample processing, and digitisation of patient samples, while diagnostics are performed by the region's pathologists in our system. We expect this type of arrangement to become increasingly common in the future.

In June, we participated in the national gastroenterology congress in Gothenburg. We are receiving increasing attention from both private and public healthcare providers in the field. Major challenges within diagnostics are common due to large sample volumes, which often lead to long response times.

We remain in a perseverance phase, in anticipation of the next major growth step. In Sweden, the growth potential in prostate cancer diagnostics lies mainly in public healthcare, as Inify already has a very strong position in outpatient urology care. The market for gastrointestinal diagnostics, where we are still in an entry phase, is divided between private and public healthcare providers.

Organisation

We continue to strengthen the organisation with staff working in or close to operations in our respective countries. We have welcomed our Laboratory Director in the UK, who brings extensive experience of laboratory operations, and have further strengthened our laboratory operations with additional Biomedical Scientists in each country.

IT security is a major focus across all sectors, not least in healthcare. During the second quarter, we added to our IT organisation by recruiting an IT Manager with broad experience in both IT and healthcare. The position will be taken up at the end of the third quarter.

Outlook

Important progress has been made during the quarter and we have achieved several crucial milestones that increase our confidence in growth going forward. In addition to the regulatory approvals for clinical operations and expanded diagnostic scope in our subsidiaries, the parent company has received certification according to ISO 13485 – further proof of a strong quality orientation in our development processes.

In line with our expectations, we anticipate that the third quarter will be affected by the Swedish holiday period, which typically results in some customer clinics being partially closed or experiencing lower patient volumes. Consequently, we expect slightly lower sales growth in Sweden during that period.

With a foundation now significantly strengthened by these achievements, I look to the future with great optimism. The clear need for our services remains unchanged, while we continuously build on our position through advances in the planned direction.

Fredrik Palm
Chief Executive Officer

Second quarter 2026

Company history and development

Inify Laboratories AB (publ) is a Swedish company with it's registered office in Stockholm, Sweden, and operates as the parent company of the Inify Laboratories group. The company was incorporated in November 2021 as a subsidiary to Context-Vision AB. Following a resolution at an extraordinary general meeting, Inify Laboratories was spun-off in February 2022 through a dividend of shares. Shortly thereafter, the company's shares were listed on Euronext Growth, Oslo.

In January 2023, a wholly owned, Swedish subsidiary was formed to support the business structure with a suitable organization. The laboratory launched it's pathology services for healthcare providers in mid June 2023.

At the end of 2024, another wholly-owned subsidiary was established, based in the UK where the establishment of the business began in 2025.

The Group provides clinical diagnostic services for prostate cancer and gastro-intestinal diagnostics.

Inify Laboratories Group

The Group consists of the parent company Inify Laboratories AB (publ), with company registration number 559345-4431, the wholly owned subsidiary Inify Laboratories Nordics AB with company registration number 559416-6828, and the wholly-owned, UK subsidiary Inify Laboratories Ltd with company number 15997568.

Inify Laboratories AB

The Parent Company's business consists of research and development, management of intangible assets, Group Management and other administrative services at Group level. The company has its own development department that further develops systems and methods and conducts research in areas such as gastrointestinal diagnostics.

Inify Laboratories Nordics AB

The Swedish subsidiary's operations mainly consist of running the day-to-day laboratory and diagnostics operations in the Group's laboratory in Solna. The company also contributes to the Group's research projects and development work.

Inify Laboratories Ltd

The subsidiary in the UK was formed in October 2024. During 2025, the subsidiary has established a local laboratory for the operation of laboratory and diagnostics operations. The laboratory started to receive patient samples in the second quarter of 2026.

Financial development

During the second quarter of 2026, the Group's operating income amounted to SEK 6,323 thousand (5,558), which corresponds to an increase compared to the same quarter previous year of 14% (54%) During the first six months the operating income amounted to SEK 12,299 thousand (10,680). The increase in sales is related to the larger volumes of patient samples that have been diagnosed during the period. In addition, the Brittish subsidiary has launched it's services in the quarter and thus started to contribute to the sales in the Group. All operating income relates to diagnostic services, both within Sweden and in the UK and has been made in SEK or GBP.

Other external costs amounted to SEK -9.5 million (-8.6) in the second quarter and to SEK -19.3 million (-17.6) during the first six months. The increase compared to the corresponding periods previous year is mainly attributable to the new subsidiary in the UK and the establishment of the new laboratory. Start-up costs and investments related to the establishment in the UK have somewhat affected the results in the beginning of 2026.

Personnel costs for the second quarter amounted to SEK -14.8 million (-12.7) and for the first six months to SEK -28.2 million (-22.5). The increase in personnel costs compared with the corresponding periods last year is a natural consequence of the fact that the organization has grown and more employees have been hired. New hires have been made on an ongoing basis in all Group companies, both Swedish and foreign.

Operating results

The group's consolidated operating result in the second quarter of 2026 was SEK -22.3 million (-17.8) and in the first six months SEK -43.9 million (-33.5). Results after financial items was SEK -21.8 million (-17.2) in the second quarter and SEK -43.3 million (-32.6) in the first six months. EBITDA for the quarter was SEK -18.1 million (-16.6) and for the first six months SEK -36.2 (31.1).

Cash flow and financing

As of June 30, 2026, liquid assets for the Group amounted to SEK 90.6 million (129.7). Cash flow for the second quarter amounted to SEK 72.6 million (-21.4). Equity at the end of the period amounted to SEK 159.7 million (142.5), resulting in an equity ratio of 90.0% (92.1%).

In December 2025, another new share issue of approximately NOK 100 million was initiated, which was completed in March 2026 when the new shares were issued. The issue amount was paid to the company in the beginning of April. The funds are mainly intended to be used for financing the expansion to the UK, develop the system for further diagnoses and as working capital during the establishement and growth phase.

Tangible and intangible assets

For intangible assets a depreciation period of 5 years is applied. For tangible assets a depreciation period of 5 years is also applied, with the exception of construction investments, which in the UK are depreciated over a period of 10 years.
Tangible assets at the end of the period amounted to SEK 72.7 million (9.6). The large increase in tangible assets is mainly attributable to investments in premises and machinery and equipment for the newly built British laboratory.

The intangible assets consist of the product Inify Prostate™, a decision support tool for prostate cancer diagnostics. It was originally developed by ContextVision, and was aquired and further developed by Inify Laboratories. It now serves as a fully integrated component of the in-house developed laboratory information system. Intangible assets at the end of the period amounted to SEK 1.2 million (3.2).

Inventories

Inventories are valued at the lower of cost and net realisable value. The cost of inventories is calculated by applying the principle of the first in, first out method (FIFO). Inventories at the end of the period amounted to SEK 1.9 million (1.0). The increase in inventory value is mainly attributable to purchases for the new laboratory in the UK.

Leases

Inify leases the combined office and laboratory facility on Campus Solna, which houses both the first laboratory and the Group's head office. The company also leases office space in Linköping, primarily intended for R&D activities. In addition, there are some smaller leasing commitments for vehicles, office equipment and laboratory equipment.

A lease agreement for a newly built facility in Milton Park outside Oxford was signed in May 2025, where the business in the UK is being established. A deposit of approximately SEK 2.9 million was paid to the landlord in connection to the signing of the agreement. A minor lease agreement for laboratory equipment for the subsidiary was signed in the end of 2025.

Employees

On June 30, 2026, the Group had a total of 39 (34) employees, whereof 32 (31) located in Sweden and 7 (3) in UK. Of these, 24 (20) were employees of the parent company, 8 (6) of the Swedish subsidiary and 7 (3) of the UK subsidiary.

Incentive program

The Company's general meeting resolved on 9 May 2022 to implement a long-term incentive program for employees (the "Employee Incentive Program") and a long-term incentive program for board members (the "Board Member Incentive Program"). The long-term incentive program consists of a maximum of 3,935,599 options, divided between the Employee Incentive Program and the Board Member Incentive Program. Assuming that all options are exercised, this will correspond to a total dilution of approximatel 4% based on the number of outstanding shares at the date of this report. Each option entitles the holder to acquire a new share or a warrant entitling to one share in the Company at an exercise price of NOK 4.80. The granted options vests over a 36-month period and may, as a general rule, only be exercised for the acquisition of new shares if the participant is still employed and the other conditions for qualified employee stock options under the Income Tax Act are met. The holder of options may exercise granted and vested options during the period from the end of the vesting period up to and including the tenth year from the date of grant.

Transactions which are eliminated by consolidation

Intra-group receivables and liabilities, income or expenses, and unrealised gains or losses arising from intra-group transactions between Group companies, are eliminated in the preparation of the consolidated financial statements. As of the balance sheet date of 30 June 2026, the parent company had group receivables and liabilities totalling SEK 101.3 million (4.1) relating to the both subsidiaries.

Related party transactions

Transactions between the parent company and its subsidiary arise naturally in the operations as, for example, premises and certain resources are shared between the companies. The group transactions for the quarter have mainly concerned interest, rents and services shared between the companies. During the second quarter, total intra-group revenues in the parent company amounted to SEK 834 thousand (719) and in the Swedish subsidiary to SEK 625 thousand (0). Except from above, there has been no other significant transactions with related parties.

Extraordinary General Meeting and new share issue

At an Extraordinary General Meeting on 6 December 2025, the EGM resolved on the issuance of 28,571,429 new shares through a guaranteed share issue with a total value of approximately NOK 100 million. The issue was made in two parts, where the first part, corresponding to approximately NOK 92 million, was directed to the largest shareholders and where the subscription period ended on December 16, 2025. The second part of the issue was directed to other shareholders and corresponds to approximately NOK 8 million. The subscription period for the second tranche ended on 26 January 2026. The payment date for both parts of the issue was 26 March 2026 and the newly issued shares were delivered during the period 30 March 2026 and the beginning of April.

Annual General meeting

On May 20, 2026, Inify held its ordinary Shareholders' Annual General Meeting. The AGM resolved with the required majority, on all matters in accordance with the Board of Directors' proposals. In summary, the main decision made where:

- To approve the annual financial accounts for 2025.
- To distribute the financial results according to proposed.
- The members of the Board of Directors and the CEO were discharged from liability.
- Remuneration to the Board of Directors was determined.
- Remuneration to the auditors will be paid against invoice.
- Board members Olof Sandén, Martin Ingvar and Magne Jordanger were re-elected as board members.
- Grant Thornton Sweden AB was re-elected as audit firm, with Joakim Söderin as acting auditor.

Risks and uncertainties

The main risk factors and uncertainties for the Group include, but are not limited to, risks related to the business and industry in which the Company operates, legal and regulatory risks, risks related to the Company's financial situation and risks relating to the shares and the listing of the shares on Euronext Growth Oslo. In addition to above, the management closely monitors and regularly evaluates any risk that may arise as a result of inflation, increasing energy prices or international instability. For further details on the company's main risk factors, please refer to the Information Document published in connection with the listing on Euronext Growth in June 2022, to the Annual Report for 2025 published on April 15, 2026 and to the national prospectus published on 7 January 2025. The risks and uncertainties associated with existing operations are not expected to have changed significantly since then.

Basis of preparation

The condensed financial statements for the second quarter 2026, ending 30 June, 2026 have been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Board's general advice BFNAR 2012:1 Annual accounts and consolidated accounts ("K3"). The condensed financial statements do not include all the information and disclosures required in the annual financial statements. For detailed information, see the company's annual report for 2025, which can be found on the website.

The functional and reporting currency of the group is Swedish kronor (SEK). All amounts, unless otherwise stated, are presented in SEK thousand.

New and changed accounting principles

No new or changed accounting principles have had effect on the accounting for the period.

Subsequent events

No other significant events have occurred during the period from the balance sheet date and the issuance of this report.

Shareholder information

- Inify Laboratories ABs shares were listed on Euronext Growth Oslo on June 20, 2022 under the ticker INIFY (ISIN SE0017486103).
- As of 30 June, 2026, the Company had a total of 107,474,845 outstanding shares. All shares have equal rights and are freely transferable.
- As of 30 June, 2026, Inify had a total of 980 shareholders, of which 3 held more than 10% each of the shares.
- Detailed information about major shareholders can be found on the company's website www.inify.com.
- The 10 largest shareholders as of 30 June, 2026 are listed in the table below.

	No of shares	%	Shareholder
1	64 578 361	60.09	Gallivant S.á.r.l.
2	12 803 511	11.91	TAURI AS
3	12 289 888	11.44	MONSUN AS
4	3 556 146	3.31	BRAS KAPITAL AS
5	2 676 218	2.49	Günther-Hanssen, Sven
6	2 567 163	2.39	Danske Bank A/S
7	1 382 243	1.29	MP PENSJON PK
8	979 708	0.91	Avanza Bank AB, MEGLERKONTO
9	770 471	0.72	OLSEN, LARS EJNAR
10	432 037	0.40	SKJELBRED, RUNE
11	5 439 099	5.06	Övriga
	107 474 845	**100**	**Totalt**

Financial calendar

This interim report was published on the company's website on the 26 of Augustl 2026. For further information, please visit www.inify.com.

25 February 2026	**Publication of Q4 and full year 2025 Financial report**
15 April 2026	**Publication of Annual Report 2025**
29 April 2026	**Publication of Q1 2026 Financial report**
20 May 2026	**Annual General Meeting**
26 August 2026	**Publication of Q2 2026 Financial report**
28 October 2026	**Publication of Q3 2026 Financial report**
24 February 2027	**Publication of Q4 and full year 2026 Financial report**

Key figures

	Q2 2026	Q2 2025	6 months 2026	6 months 2025	Full year 2025
Number of shares at period end	107 474 845	78 903 416	107 474 845	78 903 416	78 903 416
Average number of shares	93 189 130	62 070 083	93 189 130	62 070 083	62 070 083
Earnings per share	-0.20	-0.22	-0.40	-0.41	-0.86
Solidity (percent)	90.0%	92.1%	90.0%	92.1%	75.8%
EBITDA	-18 147	-16 634	-36 237	-31 129	-64 797

The company use some figures that are considered as Alternative Performance Measures.
Please see description under section Alternative Performance Measures and Definitions.

Consolidated income statement in summary SEK 1000

	Q2 2026	Q2 2025	6 months 2026	6 months 2025	Full year 2025
Net sales	6 323	5 558	12 299	10 680	22 006
Other income	1 308	45	1 630	101	222
Total operating income	**7 631**	**5 603**	**13 930**	**10 782**	**22 228**
Cost of goods	-882	-895	-1 769	-1 652	-3 403
Other external costs	-9 460	-8 585	-19 336	-17 622	-35 643
Other operating expenses	-679	-66	-838	-143	-877
Personnel costs	-14 758	-12 691	-28 199	-22 493	-47 102
Depreciation	-4 187	-1 199	-7 686	-2 372	-4 860
Operating results	**-22 335**	**-17 833**	**-43 923**	**-33 501**	**-69 657**
Interest income	519	661	610	945	1 850
Interest cost	-5	-5	-4	-4	-79
Results after financial items	**-21 821**	**-17 177**	**-43 317**	**-32 559**	**-67 886**
Tax	0	0	0	0	0
Net results	**-21 821**	**-17 177**	**-43 317**	**-32 559**	**-67 886**

Consolidated statement of comprehensive income SEK 1000

	Q2 2026	Q2 2025	6 months 2026	6 months 2025	Full year 2025
Net result for the period	-21 821	-17 177	-43 317	-32 559	-67 886
Other comprehensive income					
Translation differences	0	36	0	-64	0
Total comprehensive income	**-21 821**	**-17 141**	**-43 317**	**-32 495**	**-68 465**

Consolidated balance sheet in summary SEK 1000

Assets	June 30, 2026	June 30, 2025	December 31, 2025
Intangible fixed assets	1 177	3 196	2 186
Tangible assets	72 231	9 588	67 399
Other financial assets	2 723	4 080	2 684
Inventories and other current assets	1 921	1 039	1 717
Current receivables	8 613	7 084	9 034
Cash and bank	90 658	129 740	57 532
Total assets	**177 324**	**154 728**	**140 552**

Equity and liabilities			
Equity	159 694	142 510	106 538
Other provisions	2 954	0	2 841
Current liabilities	14 676	12 218	31 173
Total equity and liabilities	**177 324**	**154 728**	**140 552**

Consolidated change in equity in summary SEK 1000

	Q2 2026	Q2 2025	6 months 2026	6 months 2025	Full year 2025
Opening balance	181 637	159 651	106 538	33 403	33 403
Total comprehensive income for the period	-21 821	-17 141	-43 317	-32 495	-67 886
Translation differences	2 215	0	2 664	0	-579
Share issue	-2 337	0	93 809	141 602	141 602
Total	**159 694**	**142 510**	**159 694**	**142 510**	**106 538**

Parent company income statement in summary SEK 1000

	Q2 2026	Q2 2025	6 months 2026	6 months 2025	Full year 2025
Net sales	834	719	1 689	1 415	2 947
Other income	1 308	45	1 630	101	222
Total operating income	**2 141**	**764**	**3 320**	**1 516**	**3 169**
Other external costs	-6 722	-7 584	-14 088	-15 660	-29 831
Other operating expenses	-678	-66	-838	-143	-876
Personnell costs	-10 120	-9 840	-19 154	-17 841	-34 227
Depreciation	-1 159	-1 153	-2 312	-2 306	-4 612
Operating results	**-16 539**	**-17 880**	**-33 073**	**-34 433**	**-66 377**
Interest income	3 973	645	5 890	911	1 790
Interest cost	-483	-4	-1	-4	-675
Results after financial items	**-13 049**	**-17 238**	**-27 184**	**-33 526**	**-65 262**
Group contribution	0	0	0	0	5 160
Results after group contribution	**-13 049**	**-17 238**	**-27 184**	**-33 526**	**-60 102**
Tax	0	**0**	0	0	0
Net results	**-13 049**	**-17 238**	**-27 184**	**-33 526**	**-60 102**

Parent company balance sheet in summary SEK 1000

Assets	June 30, 2026	June 30, 2025			December 31, 2025
Intangible fixed assets	1 177	3 196			2 186
Tangible assets	4 110	6 527			5 230
Other financial assets	244	1 119			244
Current receivables	106 547	14 332			67 978
Cash and bank	80 140	124 146			48 578
Total assets	**192 219**	**149 319**			**123 546**
Equity and liabilities					
Equity	180 003	139 954			113 378
Current liabilities	12 216	9 365			10 168
Total equity and liabilities	**192 219**	**149 319**			**123 546**

Parent company change in equity in summary SEK 1000

	Q2 2026	Q2 2025	6 months 2026	6 months 2025	Full year 2025
Opening balance	193 052	157 192	113 378	31 878	31 878
Total comprehensive income for the period	-13 049	-17 238	-27 184	-33 526	-60 102
Share issue	0	0	93 809	141 602	141 602
Total	**180 003**	**139 954**	**180 003**	**139 954**	**113 378**

Signatures

The board and the CEO certify that this interim report for the period 1 April – 30 June 2026 to the best of our knowledge, includes a fair and true review of the company's significant events, operations, financial position, results and related party transactions, and also describes the significant risks and uncertainties that the company faces. This report has not been reviewed by the company's auditors.

The interim report was signed by all on 25 August, 2026

Olof Sandén
Chairman of the board

Fredrik Palm
CEO

Martin Ingvar
Boardmember

Magne Jordanger
Boardmember

Alternative performance measures and definitions

In its financial reports, the company presents certain financial measures, including Key Figures, which are considered as Alternative Performance Measures (APM). The company believes that these figures provide useful supplementary information to investors and the company's board and management as they enable a better evaluation of the company's financial performance. Because not all companies calculate the financial figures in the same way, these are not always comparable to measures used by other companies.

Key figure	Definition	Motivation for usage
Earnings per share after tax (Return on equity)	Net result for the period divided by the number of outstanding shares at period end.	Earnings per share shows the company's results in relation to shares, and provides additional information regarding the company's profitability.
Solidity (Equity ratio)	Equity at period end as a percentage of total assets.	The equity ratio shows the company's long term ability to pay its debts and is a complement to other key figures. It helps assess the possibility of dividends.
EBITDA	Earnings before interest, taxes, depreciation and amortization. Operating profit/loss before interest, taxes, impairment and depreciation/amortization.	EBITDA shows the company's underlying development, which is valuable as an indication of the company's underlying cash-generating capacity.

Definitions

Accreditation
Accreditation is a formal recognition that an organization is competent to perform specified tasks in testing, inspection and certification.

Artificial Intelligence (AI)
Artificial Intelligence is the intelligence exhibited by machines or software.

Biopsy
A small tissue sample.

Digital Pathology
Digital pathology refers to the digital images of histopathology samples. The digitalization is achieved by scanning the prepared samples.

Endoscopy
The use of a flexible tube with a camera, known as an endoscope, to inspect the inside of different organs. An endoscope that is used to investigate the stomach is called a gastroscope and an endoscope for examination of the colon is called a colonoscope.

Gastroenterology
An examination of the gastro-intestinal tract with an endoscope. Using the endoscope it is possible to take tissue samples and remove pre-cancerous lesions.

GI
Gastro-intestinal.

Histopathology
Examination of tissue specimens to study the visible manifestations of disease.

Image analysis
Processing a digital image in order to describe/classify its contents or to extract quantitative measurements.

LIS
Laboratory Information System

Machine Learning
Machine learning is the study of computer algorithms that automatically improve through experience.

MDT
Multidisciplinary Team Meeting is a meeting of professionals from one or more clinical disciplines who together make decisions regarding recommended treatment of individual patients.

NHS
National Health Service.

Pathology report
A medical report provided to the referring physician that describes the characteristics of a piece of tissue, blood, or body organ that has been removed from the body.

Referral/request
Order from a physician for a diagnostic examination of a specimen of tissue or other samples from a patient.

Specimen
Part of a human body (e.g., Biopsy Specimen) or organ that is to be examined by the laboratory.

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations. Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.